- Home
- WTI vs SLN Comparison
WTI vs SLN Comparison
Compare WTI & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WTI
- SLN
- Stock Information
- Founded
- WTI 1983
- SLN 1994
- Country
- WTI United States
- SLN United Kingdom
- Employees
- WTI N/A
- SLN N/A
- Industry
- WTI Oil & Gas Production
- SLN Biotechnology: Pharmaceutical Preparations
- Sector
- WTI Energy
- SLN Health Care
- Exchange
- WTI Nasdaq
- SLN Nasdaq
- Market Cap
- WTI 332.3M
- SLN 345.3M
- IPO Year
- WTI 2005
- SLN N/A
- Fundamental
- Price
- WTI $1.88
- SLN $6.70
- Analyst Decision
- WTI
- SLN Buy
- Analyst Count
- WTI 0
- SLN 6
- Target Price
- WTI N/A
- SLN $39.67
- AVG Volume (30 Days)
- WTI 1.5M
- SLN 194.5K
- Earning Date
- WTI 11-05-2025
- SLN 11-06-2025
- Dividend Yield
- WTI 2.13%
- SLN N/A
- EPS Growth
- WTI N/A
- SLN N/A
- EPS
- WTI N/A
- SLN N/A
- Revenue
- WTI $500,094,000.00
- SLN $25,830,000.00
- Revenue This Year
- WTI $6.78
- SLN N/A
- Revenue Next Year
- WTI $4.44
- SLN N/A
- P/E Ratio
- WTI N/A
- SLN N/A
- Revenue Growth
- WTI N/A
- SLN 40.39
- 52 Week Low
- WTI $1.09
- SLN $1.97
- 52 Week High
- WTI $2.59
- SLN $12.80
- Technical
- Relative Strength Index (RSI)
- WTI 42.90
- SLN 53.16
- Support Level
- WTI $1.83
- SLN $6.59
- Resistance Level
- WTI $2.08
- SLN $7.00
- Average True Range (ATR)
- WTI 0.11
- SLN 0.52
- MACD
- WTI -0.02
- SLN -0.06
- Stochastic Oscillator
- WTI 16.22
- SLN 56.60
About WTI W&T Offshore Inc.
W&T Offshore Inc is an oil and gas exploration and production company. The company's exploration operations are focused in the Gulf of Mexico, where it drills for oil and gas. The company engages in both deepwater drilling and shallow-water shelf drilling. W&T Offshore extracts crude oil, natural gas, and natural gas liquids, which are then sold directly at the wellhead. Overall, crude oil accounts for the majority of company's revenue, with natural gas accounting for a much smaller portion.
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.